Last reviewed · How we verify
Hydrochlorothiazide (HCT)
Hydrochlorothiazide (HCT) is a Thiazide diuretic Small molecule drug developed by Takeda. It is currently FDA-approved for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease.
Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, promoting water and electrolyte excretion to reduce blood volume and blood pressure.
Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, promoting water and electrolyte excretion to reduce blood volume and blood pressure. Used for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease.
At a glance
| Generic name | Hydrochlorothiazide (HCT) |
|---|---|
| Sponsor | Takeda |
| Drug class | Thiazide diuretic |
| Target | Sodium-chloride cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
As a thiazide diuretic, HCT blocks the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, preventing reabsorption of sodium and chloride. This osmotic effect increases urine output and reduces plasma volume, leading to decreased cardiac preload and peripheral vascular resistance. The resulting blood pressure reduction makes it effective for hypertension management, often as a first-line agent.
Approved indications
- Hypertension
- Edema associated with congestive heart failure
- Edema associated with renal disease
- Edema associated with hepatic cirrhosis
Common side effects
- Hypokalemia
- Hyperglycemia
- Hyperuricemia
- Hyponatremia
- Hypotension
- Dizziness
- Headache
- Photosensitivity
Key clinical trials
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control (PHASE3)
- Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control (PHASE3)
- Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study) (PHASE1)
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- Phototoxicity of Frequently Prescribed Medicines (NA)
- Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg (PHASE1)
- Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydrochlorothiazide (HCT) CI brief — competitive landscape report
- Hydrochlorothiazide (HCT) updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about Hydrochlorothiazide (HCT)
What is Hydrochlorothiazide (HCT)?
How does Hydrochlorothiazide (HCT) work?
What is Hydrochlorothiazide (HCT) used for?
Who makes Hydrochlorothiazide (HCT)?
What drug class is Hydrochlorothiazide (HCT) in?
What development phase is Hydrochlorothiazide (HCT) in?
What are the side effects of Hydrochlorothiazide (HCT)?
What does Hydrochlorothiazide (HCT) target?
Related
- Drug class: All Thiazide diuretic drugs
- Target: All drugs targeting Sodium-chloride cotransporter (NCC)
- Manufacturer: Takeda — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Edema associated with congestive heart failure
- Indication: Drugs for Edema associated with renal disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing